The document discusses updates on clinical trials at Dana Farber Cancer Institute for adolescents and young adults (AYA) with acute leukemia. It aims to identify differences in presenting characteristics and chemotherapy side effects between children and adults with acute leukemia, and determine which components of childhood acute lymphoblastic leukemia treatment regimens differ from those historically used for adults.

1. Update on Dana Farber Trails for AYA with
Acute Leukemia
Lewis Silverman, M.D.
Dana-Farber Cancer Institute
Boston, MA
Objectives:
• Identify differences in presenting characteristics of children and adults with all
(including phenotype and chromosomal)
• Identify age-related difference in chemotherapy side effects that may impact
outcome
• Indentify components of childhood; all treatment regimens which are different
those historically used for adults with all